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Abstract
Background: The number and functional activity of circulating progenitor cells (CPCs) is altered in diabetic patients.
Furthermore, reduced CPC count has been shown to independently predict cardiovascular events. Validation of CPCs as a
biomarker for cardiovascular risk stratification requires rigorous methodology. Before a standard operation protocol (SOP)
can be designed for such a trial, a variety of technical issues have to be addressed fundamentally, which include the
appropriate type of red blood cell lysis buffer, FMO or isotype controls to identify rare cell populations from background
noise, optimal antibody dilutions and conditions of sample storage. We herein propose improvements in critical steps of
CPC isolation, antigenic characterization and determination of functional competence for final application in a prospective
investigation of CPCs as a biomarker of outcome following acute myocardial infarction.
Methods and Findings: In this validation study, we refined the standard operating procedure (SOP) for flow cytometry
characterisation and functional analysis of CPCs from the first 18 patients of the Progenitor Cell Response after Myocardial
Infarction Study (ProMIS). ProMIS aims to verify the prognostic value of CPCs in patients with either ST elevation or non-ST
elevation myocardial infarction with or without diabetes mellitus, using cardiac magnetic resonance imaging (MRI) for
assessment of ventricular function as a primary endpoint. Results indicate crucial steps for SOP implementation, namely
timely cell isolation after sampling, use of appropriate lysis buffer to separate blood cell types and minimize the acquisition
events during flow cytometry, adoption of proper fluorophore combination and antibody titration for multiple antigenic
detection and introduction of counting beads for precise quantification of functional CPC activity in migration assay.
Conclusion and Significance: With systematic specification of factors influencing the enumeration of CPC by flow
cytometry, the abundance and migration capacity of CPCs can be correctly assessed. Adoption of validated SOP is essential
for refined comparison of patients with different comorbidities in the analysis of risk stratification.
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Introduction
Myocardial infarction (MI) is the irreversible necrosis of cardiac
muscle following prolonged ischemia. It remains one of the most
common causes of morbidity and mortality despite new treatment
and management systems [1]. Circulating biomarkers have been
the focus of recent research in order to improve risk assessment,
diagnosis, and prognosis of cardiovascular disease. Single or
combined biomarkers have been also used for prediction of
functional outcome after an MI, as verified by echocardiography
or cardiac magnetic resonance imaging (MRI). However,
circulating biomarkers suffer a number of limitations. The
introduction of cellular biomarkers may represent an important
advancement in the evaluation of risk stratification, because the
number and function of progenitor cells could directly and
simultaneously address pathogenic and reparative mechanisms [2].
In particular, circulating progenitor cells (CPCs) have been
proposed to be associated with occurrence and prognosis of MI
[3]. Subsets of this heterogeneous population possess pluripotent
potential and may help myocardial healing by direct participation
in cardiac neovascularisation and remodelling, whereas the
monocyte component is seemingly engaged in the paracrine
modulation of the above phenomena [4]. Strong evidence
indicates that CPCs are mobilized after an MI in response to
cytokine stimulation, with the extent of mobilization being
positively correlated with indices of cardiac contractility during
recovery [5,6,7]. Risk factors may decrease CPC mobilization
after a heart attack, but the findings of studies investigating CPC
mobilization in diabetes are controversial. A negative correlation
between CPC number and cardiovascular complications was
found in Type 2 diabetes [8,9]. Other studies suggest that the
viability and migration capacity of CPCs are impaired in diabetic
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patients, whereas CPC counts are not dramatically altered
[10,11,12]. Furthermore, the usefulness of CPCs for cardiovascu-
lar risk stratification in diabetic versus non-diabetic patients
remains undefined.
We have designed an observational clinical trial, the Progenitor
cell response after Myocardial Infarction Study (ProMIS), to verify the
prognostic value of CPCs in post-MI patients with or without type
2 diabetes, using cardiac MRI as primary endpoint. Here, we
report the introduction of a refined SOP for optimization of CPC
isolation, enumeration and qualification in functional assays
Results
Analyses were carried out on the first patients recruited to the
ProMIS study, without knowledge of the diabetic status or MI
classification (i.e. ST segment elevation myocardial infarction -
STEMI - or Non-ST Segment Elevation Myocardial Infarction -
NSTEMI -). In order to provide reliable and reproducible data for
this trial, we first designed the experimental strategy based on the
literature and our previous experience. Furthermore, to fulfil the
requirements of the International Conference on Harmonisation
(ICH) - Good Clinical Practice (GCP), we considered all the
critical issues relevant to each individual step of the SOP as shown
in Figure 1. Particularly, we validated or optimized some critical
technical points that have potential effects on the ultimate
outcome of the trial in a sequential manner.
Difference in FACS layout of lyse/wash and lyse/no-wash
procedures of blood samples
After immunostaining of human peripheral blood samples with
cell surface markers, RBCs are often lysed in order to separate
blood cell types and minimize the acquisition events during flow
cytometry. We first investigated whether the simplified lyse/no-
wash procedure, which reduces sample manipulation, would give
improved cell yield over lyse/wash. As shown in Figure 2, from
the samples subjected to lyse/wash step, lymphocyte and
monocyte populations were separated nicely on the plot of FSC
vs. SSC thus allowing easy gating of those cell sub-populations
(Figure 2A). From the samples subjected to lyse/no-wash step,
lymphocyte and monocyte populations could still be detected on
the plot of FSC vs. SSC (Figure 2B); however, they were not as
distinctive as the profile from the lyse/wash step. When dead cells
were stained with the Fixable Viability Dye eFluorH 780, they
could be better identified from the lyse/wash step (Figure 2C)
than from the lyse/no-wash one (Figure 2D). However, the
abundance of CD133+ cells enumerated by both methods was
similar (Figure 2E & F). Furthermore, we found that the samples
prepared by the lyse/no-wash approach frequently blocked the
fluid system in the flow cytometer and it took much longer to
acquire a given number of events.
Comparison of RBC lysis buffers
There are two main types of RBC lysis buffers, i.e. with or
without a fixative such as paraformaldehyde. We investigated the
effect of fixative in the RBC lysis buffers on cell characterization by
FACS in 3 replicates from each of 3 patients (18 samples in total; 3
patients63 replicates62 lysis buffers). As shown in Figure 3,
typical blood cell populations were separated well using either a
fixative-containing lysis buffer (BD) or a fixative-free variant
(Invitrogen). However, the distributions of the typical cell
populations were not equally distinctive in the scatter plots of
FSC vs. SSC. It appeared that blood cells treated with fixative-free
lysis buffer spread more along the scattergram (Figure 3B) as
compared with the fixative-containing one (Figure 3A). After
normalization by counting beads, samples treated with fixative-
free lysis buffer yielded approximately 1.85-fold higher levels of
total cells (P,0.001) and lymphocytes (P,0.001) and 1.28 fold
higher levels of monocytes (P = 0.001) (Figure 3C). As shown in
Figure 3D, the percentage of lymphocytes over total cells was
similar between the two experimental conditions (P = 0.74),
whereas the percentage of monocytes was lower in the samples
using the fixative-free lysis buffer as compared with the fixative-
containing lysis buffer (P = 0.001).
Interference of the multiple antibodies conjugated with
different fluorophores
Because there is no single antigenic marker for CPC
identification, multiple antibodies conjugated with a panel of
fluorophores are commonly used for flow-cytometry profiling.
Therefore, it is extremely important to test and eventually
minimize the interference among different fluorophores. Particu-
larly, we investigated whether different PE-conjugated antibodies
(CXCR4, CD164, CD117 and TrkA) have an effect on the
enumeration of three commonly-used progenitor cells markers,
KDR-FITC, CD133-APC and CD34-PE-Cy7 in individual
samples (60 samples in total; 4 patients63 replicates65 antibod-
ies). As shown in Figure 4A, the presence of the selected PE
conjugated antibodies appeared to have an effect on enumeration
of KDR-FITC positive cells (P = 0.023; F-test). However, the
presence of those PE-conjugated antibodies had no effect of the
quantification of the selected cell populations expressing CD133-
APC (P = 0.16; F-test) or CD34-PE-Cy7 (P = 0.70; F-test), as
shown in Figure 4C and Figure 4B, respectively.
Fluorescence-minus-one controls are necessary to
quantify rare circulating progenitor cells
CPCs are a relatively rare component of the circulating
leukocyte population even after mobilization following an acute
MI. The fluorescence-associated rare events can be easily
shadowed by auto-fluorescence or spillover contamination from
other fluorophores. Therefore, when different fluorophore-conju-
gated antibodies are combined together, it is important to apply
appropriate controls for background subtraction. We particularly
investigated the effect of fluorescence minus one (FMO) controls
and full isotype controls. As shown in Figure 5 (A, B and C), the
combinations of isotype controls showed background noise on
each single channel involved (i.e. PE, APC and PE-Cy7), probably
due to potential non-specific binding and/or fluorophore spillover
contamination. Importantly, reference to the individual FMO
controls allowed defining the appropriate gating (Figure 5 D, E
and F), for determination of the number of a particular cell
population (Figure 5 G, H and I). When tandem fluorophores
such as PE-Cy7 were employed, isotype controls showed relatively
higher background noise (Figure 5C), therefore the role of a
FMO control was even more relevant (Figure 5F).
Titration of each individual antibody is essential before
combination for CPC enumeration
Before selected antibodies were applied for CPCs enumeration,
we validated their dose dependence by serial titration. As shown in
Figure 6, the signals obtained from some antigenic markers such
as CD34, CD117 and TrkA are typically dose-dependent and
reach saturation when a high dose of antibodies is used. The signal
from samples stained with CD133 however reached a steep peak
followed by gradual decline when antibody concentration was
increased, which fits a parabolic-curve like pattern. The signal
from samples stained with CD164 was blunted unless a high
Circulating Progenitor Cells in Infarction
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concentration of antibody was used. The signal from samples
stained with KDR was always dim even when an excess of
antibody was used. The optimal concentration of each individual
antibody was not always as recommended by the vendor (Green
Bar, Figure 6) thus implying the necessity of validation by the
customer.
The freshness and quality of the PB samples are relevant
for the evaluation of CPCs
Patients with MI refer to the clinic as emergencies at any time of
day or night. Therefore, in order to maximise the opportunity for
recruiting patients into a study like ProMIS, we investigated the
effect of storing samples at 4uC for 24 hr before subjecting samples
to immunostaining for flow cytometry analysis using data from 4
patients (24 samples in total; 4 patients63 replicates62 time
points). As shown in Figure 7, it appeared that there is higher
percentage of lymphocytes, but no change of the monocyte
population after storage for 24 hrs (Figure 7A). Furthermore, the
storage dramatically affected the quantification of distinct CPC
populations with a CD34+, CD133+, KDR+ or CD117+
phenotype (Figure 7B–E). After mononuclear cells were isolated
for functional tests such as migration assay, freshly processed
samples appeared clear (Figure 7F), while clotting blocks were
often observed from the tube containing a stored sample
(Figure 7G). Clotting also occurred when venipuncture was
technically difficult. These samples yielded artificially low levels of
CPCs by flow cytometry.
Evaluation of migration index using counting beads and
acquisition time
The migration assay is routinely used to estimate one
fundamental functional property of mononuclear cells or isolated
CPCs, e.g. the responsiveness to a chemoattractant. Flow
cytometry can be subsequently applied to characterize distinct
CPCs in the migrated and non-migrated fractions. However, it is
not possible to quantify absolute cell numbers directly using the
majority of flow cytometers such as a FACS Canto II. Therefore,
following transwell migration of leukocytes toward SDF-1 or NGF,
we compared the migration indexes which are normalized by
using either the addition of counting beads or calculating
acquisition time by the flow cytometer in 20 samples (10
patients62 replicates). When SDF-1 was used as chemoattractant,
Figure 1. SOP of the ProMIS. Left: Characterization of circulating progenitor cells (CPCs) and monocytes in peripheral blood of MI patients. Right:
Evaluation of migration capacity of CPCs by flow cytometry. PB, peripheral blood; TP, time point; WBC, white blood cell; CPC, circulating progenitor
cell; MNC, monocyte; RBC, red blood cell.
doi:10.1371/journal.pone.0030389.g001
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the Bland-Altman plot was shown in Figure 8A with the 95%
limits of agreement between two techniques ranging from 20.27
to +0.40. When NGF was used as a chemoattractant, the Bland-
Altman plot was shown in Figure 8B with the 95% limits of
agreement between the two techniques ranging from 20.30 to
+0.52 (Figure 8B). These data indicate that both techniques can
be used to evaluate migration activity of CPCs to SDF-1 or NGF-
1. However, the acquisition method is based on the assumption of
consistent speed during data collection, which is difficult for
normalization because approximately just 11.59% of cells
migrated to SDF (95% CI of geometric mean, 9.69–13.86%,
n = 28), and the flow cytometric speed should be adjusted to allow
detection accuracy for the non-migrated samples while reaching
maximal acquisition for the migrated samples. Therefore, it may
be more reliable to incorporate counting beads in order to
precisely calculate the number of cells. Using the counting-bead
Figure 2. Comparison of lyse-wash and lyse-no-wash procedures. Whole blood samples were stained with progenitor cell markers and
eFluor 780 fixable viability dye. Following RBC lysis with FCS lysis buffer (BD Bioscience), stained samples were washed with PBS (A, C and E) or stored
at 4uC for subsequent FACS analysis within 5 days (B, D and F).
doi:10.1371/journal.pone.0030389.g002
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based method, the migration of PB WBCs with response to SDF-1
or NGF was evaluated (Figure 8C). We demonstrated that the PB
WBCs from MI patients migrated to SDF-1 but not NGF, which
were indicated by one way ANOVA with LSD post hoc correction
(P = 0.022 for SDF-1 and P = 0.695 for NGF, n = 28).
Discussion
This study describes several technical implementations for
enumerating and characterising CPCs in the ProMIS trial.
We first demonstrated that the lyse-wash step is superior to the
lyse-no-wash step after immunostaining of peripheral blood. Using
the lyse-and-wash technology, blood cell populations can be
separated better and dead cells can be easily excluded either by a
FSC-SSC plot or a fluorophores-conjugated viability dye.
Furthermore, the sample solution prepared by a lyse-no-wash
step is sticky and can block the fluid system of a cytometer like the
BD Canto II. Samples need to be highly diluted with H2O when a
lyse-no-wash method is applied, which results in extension of the
running and analyse time of flow cytometry and thus becomes
cost-inefficient. However, we acknowledge the appropriateness of
the lyse-no-wash technique under specific circumstances; it is clear
that the minimal manipulation of blood cells leads to less cell loss
and less disturbance of fragile cells, which is particularly the case
when one or two-colour markers (e.g. CD34) are of interest and it
is not necessary obtain a large number of captured cell events (e.g.
. = 16105 lymphocytes) [14,15]. However, when multicolour
antigenic analysis is required and time/cost effects have to be
considered, the lyse-wash technique may provide more advantages
[16].
Next, we compared the effect of RBC lysis buffers with or
without the fixative paraformaldehyde. The fixative-free RBC lysis
Figure 3. Effect fixative-containing RBC lysis buffer on cell yield. (A) Typical scatter plot of samples treated with fixative-containing lysis
buffer. (B) Typical scatter plot of samples treated with fixative-free lysis buffer. (C) Effect of fixative in RBC lysis buffer on cell yield during FACS
acquisition using counting beads compensation. (D) Effect of fixative in RBC lysis buffer on the percentage of lymphocyte and monocyte populations.
Data are presented as geometric means with 95% confidence intervals.
doi:10.1371/journal.pone.0030389.g003
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buffer markedly increased the yield of the total cells and
lymphocyte population. The presence of paraformaldehyde in
the lysis buffer did not have an effect on the yield of monocytes by
flow cytometry. Fixation during RBC lysis leaves white cell
populations (e.g. CD34+ cells) in sticky blood and leads to their loss
during washing and resuspending, which might explain why the
fixative-free lysis buffer provides a higher yield of cells after the
lyse-wash procedure [17]. Therefore, fixative-free RBC lysis buffer
is definitely the best option for the quantification of rare progenitor
cells in blood by flow cytometry.
Although flow cytometry equipped with multiple lasers and
fluorescence detectors is sensitive enough to identify rare cells in
blood, variation in data characterising CPCs can be caused by
various factors such as autofluorescence, cell aggregation, non-
specific immunostaining of other cell types including dead cells/
debris, non-lysed erythrocytes, platelets as well as system fluctuation
due to excessive speed, inadequate cleaning or blocking. We tested
the reproducibility of a cell population indicated by a fluorophores-
conjugated marker in the presence of other markers by repetition.
Sometimes other fluorophore-conjugated antibodies can interfere
with quantification of CPCs. Therefore, when a study is carried out,
protocols must be designed with strict validation of antibodies,
which must be used consistently. According to good laboratory
practice, repetition (e.g. duplicate/triplicate tests) is ideal, yet flow
cytometric data are often presented as a single test to reduce costs.
When rare CPC populations are enumerated, attention must be
given to potential contamination during the sample process, for
instance, immunostaining with multiple fluorophores. The tech-
nology of FMO controls has been reported to be necessary to
accurately identify positive cells in the fully stained sample after
multicolour flow cytometry [18,19]. In a study on rare CPC
enumeration, this is definitely the case. Without the FMO
controls, it is also difficult to set up proper gating due to the
accumulation of background noise by spectral spillover from
irrelevant fluorophores. This is more obvious when tandem
fluorophores such as PE-Cy7 are combined.
Due to the complexity inherent to CPC heterogeneity, the
application of multiple antibodies is often necessary. However, the
selection of different photospheres can still be tricky. Our titration
data suggest that the efficiency of immunostaining using an
individual rare progenitor cell marker can be highly heteroge-
neous. Before antibodies are selected and combined, it is essential
to perform individual dose-titration tests in order to identify the
optimal strategy.
Although fresh samples are ideal, researchers would like to
understand whether CPCs in peripheral blood are stable over
short periods of time since being able to store samples for a few
hours makes a study more practicable. Therefore, we investigated
the effect of blood freshness on CPC-marker expression. After
24 hours of storage at 4uC, both the percentage of lymphocytes
and expression of most CPC markers (e.g. KDR, CD133 and
CD117) decreased, suggesting that CPCs in peripheral blood are
fragile or the antigen can be downregulated or internalized during
storage. Furthermore, when white blood cells in 24-hour blood are
isolated by Histopaque 1077, clotting can be observed on the
porous barrier in a LeucoSep tube, which may potentially cause
degradation of viable cells and deterioration of cellular functions in
vitro. Therefore, when PB samples are used for the evaluation of
CPCs, the gold standard should remain fresh blood, and ‘the
fresher the better’ [20]. Practically, a same-working-day strategy
(e.g. 8 hrs) should be applied for a study, but this operative
window may remarkably reduce the possibility to recruit patients
with an acute MI who can present at any time of day.
Application of flow-cytometry to the CPC migration assay
provides the means to understand how many and which CPCs
respond to a particular cytokine. However, reproducibility could
be reduced due to cell loss during multiple and tedious
manipulation during preparation of samples for analysis. In order
to enable robust high-throughput studies and track migration in a
real-time manner, some improved techniques emerged which
include OrisTM Cell Migration Assay (Platypus technologies,
Madison, WI) and FluoroblokTM (BD Biosciences, Bedford, MA).
These techniques would be encouraged to integrate cutting-edge
high throughput migration methods with flow cytometry in future.
In conclusion, although the interest in CPCs is steadily
increasing, the lack of a consensus on standardised protocols
remains a barrier to clinical exploitation [21,22]. In this study, we
addressed some critical steps instrumental to optimal enumeration
and characterisation of CPCs in cardiovascular patients. Our
findings may be also applicable for other clinical trials when CPCs
need to be enumerated, for instance, stroke, and chemo-/radio-
therapies for cancer patients.
Figure 4. Representative graphs showing the interference of different fluorophore-conjugated antibodies. Different PE-labelled
antibodies were added to KDR-FITC, CD133-APC and CD34-PECy7 in individual samples. Triplicate tests were performed. Data are presented as
geometric means with 95% confidence intervals.
doi:10.1371/journal.pone.0030389.g004
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Materials and Methods
Study design
We selected four cohorts for assessment in ProMIS, namely
patients presenting with either ST elevation MI (STEMI) or non-
ST-elevation MI (NSTEMI), with or without type 2 diabetes
mellitus. We are recruiting 18 patients prospectively for each
cohort, thus 72 patients in total. Eligibility criteria are as follows:
patients presenting with clinical features of STEMI or NSTEMI
within 24 hours of symptom onset, aged 40 to 75 yrs on
admission, and resident within 40 miles of the study centre.
Patients are excluded if they have anaemia (haemoglobin,
10 mg/dL), cardiogenic shock, significant renal impairment
(eGFR,50 mL /min per 1.73 m2), haemodynamic instability,
contraindications to undergoing a magnetic resonance scan (e.g.
metallic implant, pacemakers, screws, claustrophobia etc), have had
previous coronary event within the last 12 weeks, are participating
in another clinical trial or show heightened anxiety during
recruitment.
Written informed consent is obtained directly from each eligible
patient before the trial. 10 mL blood sample (TP1 sample) is then
obtained within 12–24 hours of the onset of symptoms for FACS
analysis. A second 50 mL blood sample (TP2 sample) is obtained
at 84–108 hours after the onset of symptoms for FACS analysis
and transwell migration assay of CPCs. Blood samples are
transferred to the laboratory at 4uC and processed within 24 hours
unless described differently. Demographic data and clinical data
including past medical history, medication history, acute investi-
Figure 5. Fluorescence minus One (FMO) controls for the quantification of rare CPC events by FACS. Isotype controls were prepared by
the combination of all the individual fluorophore-conjugated isotype control antibodies (A, B and C). FMO controls were prepared like isotype
controls without adding a particular fluorophore-conjugated isotype control antibody, for instance fluorescence minus PE (D), fluorescence minus
APC (E), fluorescence minus PE-Cy7 (F), respectively. The gating for each channel was defined to exclude nearly all background from the FMO
controls on the 2D plots of FSC-H vs. individual fluorescence (e.g. PE, APC or PE-Cy7). Certain cell populations including CD117+ (G), CD133+ (H) and
CD34+ (I) from a single sample were enumerated according to the gating strategy as above.
doi:10.1371/journal.pone.0030389.g005
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gations and treatment information are recorded in a case report
form (CRF). Patients have a cardiac magnetic resonance (CMR)
assessment on day 5 after presentation to determine the extent of
MI injury (scar volume) and then 3 months later to assess the final
volume of the scar. The protocol for this study was approved by
the UK NHS Research Ethics Committee (REC reference
number: 09/H0104/58).
FACS analysis
One hundred mL of peripheral blood samples collected in
ethylenediaminetetraacetic acid (EDTA) containing tubes are
incubated for 30 min at 4uC with mouse-anti-human monoclonal
antibodies including kinase insert domain receptor (KDR) conju-
gated with fluorescein isothiocyanate (FITC) (R&D Systems,
Minneapolis, MN, USA), CD133/2 (clone 293C3) conjugated with
allophycocyanin (APC) (Miltenyi Biotec, Bergisch Gladbach,
Germany), CD34 (clone 8G12) conjugated with phycoerythrin-
Cy7 (PE-Cy7) (BD Bioscience, San Jose, CA), CXCR4 (CD184)
conjugated with PE (Invitrogen, Paisley, UK), CD164 (clone N6B6)
conjugated with PE (Becton Dickinson, San Jose, CA), CD117/C-
KIT (clone 104D2) conjugated with PE (Invitrogen, Paisley, UK),
TrkA (Clone 165131) conjugated with PE (R&D Systems,
Minneapolis, MN, USA), CD14 conjugated with FITC and
CD16 conjugated with PE (Invitrogen, Paisley, UK) , respectively.
Additional samples are stained with appropriate isotype control
antibodies following the fluorescence-minus-one method. The
isotype control antibodies we used were Mouse IgG1-FITC
(Invitrogen, Paisley, UK), Mouse IgG1-PE (Invitrogen, Paisley,
UK), Mouse IgG2b-APC (Miltenyi Biotec, Bergisch Gladbach,
Germany) and Mouse IgG1 PE-Cy7 (BD Bioscience, San Jose, CA).
The following steps are then carried out in sequence:
N Cells are lysed with FACS lysis buffer (BD Bioscience, San
Jose, CA) for the lyse/no wash procedure.
N For the lyse/wash procedure, samples are subjected to lysis of
red blood cells (RBC) for 15 min at room temperature using
either 16FACS lysis buffer (BD Bioscience, San Jose, CA) or
high yield fixative free lysis buffer (Invitrogen, Paisley, UK).
N Cells are spun down for 10 min at 3006g and then stained
with the Fixable Viability Dye eFluorH 780 (eBioscience, San
Diego, CA) for 30 min at 4uC.
N Cells are washed with PBS and fixed with 1% paraformalde-
hyde (PFA). AccuCheck counting beads are occasionally
included for cell quantification according to the manufactur-
er’s instructions (Invitrogen, Paisley, UK).
N Flow cytometric acquisition is performed on a FACS Canto II
system (BD Bioscience, San Jose, CA) within one week. FACS
analysis is carried out using the FACS Diva 6.0 software (BD
Bioscience, San Jose, CA).
Migration assay
Peripheral blood samples at TP2 in EDTA tubes are diluted
with PBS supplemented with 2 mM EDTA and 0.5% BSA (v/v,
Figure 6. Titration of individual CPC markers before multicolour flow cytometry. Data are presented as geometric means with 95%
confidence intervals. When without dilution, the volume of each antibody used for staining 100 m0 of blood is: 10 m0 of CD133-APC (50 CD133), 5 mL
of CD34-PECy7 (50 mg/mL), 20 mL of KDR-FITC (50 mg/mL), 20 mL of CD164-PE (50 mg/mL), 5 mL of CD117-PE (50 mg/mL), and 20 mL of CD164-PE
(25 mg/mL), respectively. The green bars show the dilution ratio of individual antibodies as recommended by vendors. The purple bars show the
optimal dilution ratio of some antibodies according to our titration tests.
doi:10.1371/journal.pone.0030389.g006
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1:1); 30 mL of diluted blood solution is then loaded in a 50-mL
LeucoSep tubes (Greiner, Frickenhausen, Germany) with 15 mL
of Histopaque 1077 (Sigma, Poole, UK) and centrifuged at 8506g
for 25 min. The buffy coat layers containing white blood cells are
collected and washed twice with sterile PBS. Cells are then
resuspended in EBM-2 (Lonza, Berkshire, UK) supplemented
with 0.1% BSA. 0.5–16107 cells/mL of cells are loaded onto the
upper part of ThinCertTM tissue culture polystyrene inserts
(452.4 mm2 culture surface, 3.0 mm pore size; Greiner BioOne,
Gloucester, UK) which are pre-assembled on 6-well plates
containing medium as above with or without 100 ng/mL of
recombinant human SDF-1a or b-NGF (PeproTech, Rocky Hill,
NJ), respectively. Cells are then incubated at 37uC in a
humidified incubator with 5% CO2 for 18 hrs. Cells from both
parts of the transwell inserts are dissociated with Accutase
(Invitrogen, Paisley, UK) and collected into FACS tubes.
Following washing using PBS, migrated and non-migrated cells
are stained with KDR-FITC, CD133/2 (293C3)-APC, CD34
(8G12)-PE-Cy7 and CXCR4 (CD184)-PE antibodies for flow
cytometry analysis as described above.
Figure 7. Effect of blood storage time on CPC profiling. Peripheral blood samples from MI patients were processed either directly (,1 hr) or
stored at 4uC for 24 hr before analysis. (A) Bar graph showing the percentage of lymphocyte and monocyte cell populations. (B, C, D and E) Bar
graph showing the percentage of CD34-PE-Cy7, CD133-APC, KDR-FITC and CD117-PE in lymphocytes, respectively before and after storage for 24 hrs.
(C and D) Representative images show that there was excessive clotting in the Leucosep tubes after leukocyte isolation when samples were stored
for 24 h at 4uC. Data are presented as geometric means with 95% confidence intervals.
doi:10.1371/journal.pone.0030389.g007
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Data analysis and statistics
Data are shown as geometric mean with 95% confidence
intervals. For the evaluation of migration capacity, following
normalization of the data using FACS requisition time or counting
beads, migrated cells (in the down part of the inserts) were divided
by the sum of the migrated cells and non-migrated cells (that were
left in the upper part of the inserts) and multiplied by 100 to give the
migration percentage. Migration index is the value of migration
percentage in a sample divided by that in the control, i.e.,
%Migration~NMigrated cells

NMigrated cellszNNon-migrated cells
 
;
Migration index~%Migration sampleð Þ

%Migration controlð Þ:
Statistical analyses were performed using regression modelling,
taking account of the repeated measurements from the same
patient. If the overall test for a difference between groups (F-test) was
statistically significant (p,0.05) then paired comparisons between
groups were made. Skewed data were transformed to the
logarithmic scale for analysis and results are presented as geometric
means with 95% confidence intervals. Model assumptions were
checked and influential outlying values were excluded. Bland and
Altman plots [13] were used to determine concordance between
techniques of migration flow cytometric measurement with the
limits of agreement defined as the mean of the difference 61.96
standard deviations. It was considered statistically significant when
P value,0.05. Analyses were carried out using Stata 11.2
(StataCorp LP 4905 Lakeway Drive College Station, Texas. USA).
Figure 8. Migration capacity of isolated leukocytes assessed using time of acquisition by FACS and counting beads. Blood was
collected at TP2 (84–108 h) post-MI and subjected to Histopaque-1077 density gradient centrifugation. The buffy coat was collected and washed in
PBS. Cells were suspended in EBM-2 medium at a density of 0.5–16107 cells/mL and loaded on 6-well tissue culture inserts (3-mm pore ThinCert;
Greiner Bio One). Medium with or without chemoattractants (i.e. SDF or NGF) was added in the bottom part of the inserts. Following transwell
migration in a humidified CO2 incubator for 18 hrs, the migrated and non-migrated cells number was evaluated by FACS analysis with the assistance
of acquisition time or counting beads. As described in Materials and Methods, migration index (ratio of migrated cell fraction in the total cells) of
each sample was then estimated using both the acquisition time-based and beads-based approaches (A and B). Migration index evaluated in the
presence of counting beads (C).
doi:10.1371/journal.pone.0030389.g008
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